Oncoc4
Business Services · Maryland, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
9640 Medical Center Dr, Rockville, Maryl...Website
www.oncoc4.comRevenue
$28.7 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About Oncoc4
OncoC4 is a clinical-stage biotechnology company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer and neurodegenerative disease. OncoC4's pipeline features assets with first-in-class and best-in-class potential targeting both novel and well validated targets across oncology and immunological diseases.Explore more
Oncoc4 Org Chart
Get the full picture
Sign in to uncover key details.
JW
Vice President, Finance
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oncoc4 your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Oncoc4 recently announced quarterly report
Website visits: Recent activity has been detected on your website
Oncoc4, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Oncoc4 has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Oncoc4 launches new products
Congratulate Masked Content for being promoted to Masked Content at Oncoc4
Click to see if Oncoc4 had a recent Job posting/layoffs
Check out if Oncoc4 is spiking on competitors!
Funding: Get notified immidiatlly once Oncoc4 has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Oncoc4
Compare insights from companies similar to Oncoc4, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Oncoc4 is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Oncoc4 is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Oncoc4.
Oncoc4 financials insights
Gather financial insights about Oncoc4, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series B
$50M
Oncoc4 Tech Stack
A closer look at the technologies used by Oncoc4
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Oncoc4 News & Media
OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors
— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous formulation designed to provide gradual systemic exposure, potentially mitigating CRS risk — ROCKVILLE, Md., Aug. 17, 2026 /PRNewswire/ -- OncoC4 Inc., a...OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease
ROCKVILLE, Md., April 9, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical stage biopharmaceutical company, today announced first participant's dosing following the clearance of the Investigational New Drug (IND) application for a Phase 1/2 clinical trial of ONC-841, the company's investigational Alzheimer's disease therapy by the National Medical Product Administration (NMPA). The clinical trial registration number is CTR20260866. ONC-841 is the world's first and only clinical stage anti-SIGLECBioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard chemotherapy and a manageable safety profile in sqNSCLCChina's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392)
Designation granted for gotistobart (BNT316/ONC392) for the treatment of patients with squamous non-small cell lung cancer (sqNSCLC), an aggressive subtype of lung cancer Breakthrough Therapy designation will allow for an expedited development and regulatory review of gotistobart in China Global pivotal PRESERVE-003 Phase 3 clinical trial in squamous non-small cell lung cancer Is Ongoing ROCKVILLE, Md., Oct. 27, 2025 /PRNewswire/ -- OncoC4 announced today that China's National Medical Product Ad
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Oncoc4
Sign Up For FreeTo access detailed company insights
OncoC4 is a clinical-stage biotechnology company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer and neurodegenerative disease. OncoC4's pipeline features assets with first-in-class and best-in-class potential targeting both novel and well validated targets across oncology and immun... Read More
